Studies

110 studies · Download as JSON

• Effects of semaglutide and empagliflozin on markers of endothelial function in persons with type 2 diabetes: A post hoc analysis of a randomized clinical trialRandomized trial · 2026 · Study tier 3 · Different population · Mixed · Unreviewed automatic assessment
• Comparative Efficacy of Tirzepatide Versus Semaglutide for Weight Loss in Adults With Overweight or Obesity: A Systematic Review and Meta-Analysis of Head-to-Head StudiesMeta-analysis · 2026 · Study tier 2 · Different population · Mixed · Unreviewed automatic assessment
• Oral semaglutide for weight loss and liver fibrosis in overweight and obesity: A randomized controlled trialRandomized trial · 2026 · Study tier 3 · Different population · Benefit · Unreviewed automatic assessment
• Reprogramming NAD+ homeostasis and FOXO3a-Nrf2 signaling mitigates bleomycin-driven pulmonary fibrosisAnimal study · 2026 · Study tier 4 · Not human evidence · Mixed · Unreviewed automatic assessment
• Comparing Cardiovascular Outcomes in New Users of Oral Semaglutide Versus Other Noninsulin Glucose-Lowering Therapies Among Adults with Type 2 Diabetes and Atherosclerotic Cardiovascular DiseaseRetrospective cohort · 2026 · Study tier 3 · Population unclear · Benefit · Unreviewed automatic assessment
• Effects of semaglutide on subclinical cardiovascular health in people with HIVRandomized trial · 2026 · Study tier 3 · Population unclear · Null · Unreviewed automatic assessment
• Semaglutide as adjunct treatment for obesity in adolescents receiving antipsychotic medication (the GOAL trial): protocol for a single-arm, open-label feasibility studyClinical trial · 2026 · Study tier 4 · Different population · Harm direction · Unreviewed automatic assessment
• Efficacy and Safety of Semaglutide According to Frailty Status: A Post Hoc Analysis of the SELECT Randomized Clinical TrialRandomized trial · 2026 · Study tier 1 · Different population · Benefit · Unreviewed automatic assessment
• Adjunctive GLP-1 receptor agonists for cardiometabolic risk in antipsychotic-treated patients: A GRADE-assessed meta-analysis of randomized trialsMeta-analysis · 2026 · Study tier 2 · Population unclear · Benefit · Unreviewed automatic assessment
• GLP-1 receptor agonist use and mental health outcomes in adolescents with obesity: a retrospective reviewCase-control · 2026 · Study tier 4 · Different population · Null · Unreviewed automatic assessment
• DUTCH weight control in atrial fibrillation study (DUTCH-WAIST) : Design and rationale of a randomised controlled trialRandomized trial · 2026 · Study tier 3 · Different population · Unclear · Unreviewed automatic assessment
• Obstructive sleep apnea, GLP-1 receptor agonist pharmacotherapy, and the oral microbiome: competing biological influences and implications for oral health monitoringPharmacovigilance · 2026 · Study tier 4 · Different population · Harm direction · Unreviewed automatic assessment
• Psychiatric Safety of GLP-1 and Dual GIP/GLP-1 Receptor Agonists in Adolescents With ObesityRetrospective cohort · 2026 · Study tier 3 · Different population · Mixed · Unreviewed automatic assessment
• GLP-1 Receptor Agonists and Musculoskeletal Outcomes: A Systematic Literature Review and Meta-AnalysisMeta-analysis · 2026 · Study tier 2 · Different population · Unclear · Unreviewed automatic assessment
• Metabolic Effects of a GLP-1 Analog Combined with Aerobic Training in Ovariectomized RatsAnimal study · 2026 · Study tier 4 · Not human evidence · Harm direction · Unreviewed automatic assessment
• Postoperative outcomes after total knee arthroplasty in type 2 diabetes mellitus patients receiving semaglutide versus tirzepatide: a propensity score-matched national research network analysisRetrospective cohort · 2026 · Study tier 3 · Different population · Unclear · Unreviewed automatic assessment
• Assessing the Association Between GLP-1 Receptor Agonists and Diabetic Foot Complications Using Real-World Pharmacovigilance Database and Mendelian RandomizationMendelian randomization · 2026 · Study tier 3 · Population unclear · Harm direction · Unreviewed automatic assessment
• Side effects of lower dose compounded semaglutide paired with a behavioral management program: A real-world retrospective studyRetrospective cohort · 2026 · Preliminary · Population unclear · Unclear · Not peer reviewed · Unreviewed automatic assessment
• Carbon Emission Impact of Semaglutide in People with Obesity in the UK Using a Disease Modelling ApproachRetrospective cohort · 2026 · Study tier 3 · Different population · Benefit · Unreviewed automatic assessment
• Semaglutide and Papillary Thyroid Carcinoma: Current Evidence on Risk, Progression, and MechanismsPharmacovigilance · 2026 · Preliminary · Different population · Null · Not peer reviewed · Unreviewed automatic assessment
• Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy: Notoriety Bias or True Ocular Toxicity?Mendelian randomization · 2026 · Preliminary · Population unclear · Harm direction · Not peer reviewed · Unreviewed automatic assessment
• Dorsomedial striatal GABA dynamics organize palatable reward consumption and are reshaped by GLP-1 receptor agonismAnimal study · 2026 · Preliminary · Not human evidence · Unclear · Not peer reviewed · Unreviewed automatic assessment
• HIF-1 plays a dual regulatory role in hippocampal neuronal PANoptosis in Alzheimer's disease via the HK2/VDAC1/NLRP3 axis and RIPK3 signalingAnimal study · 2026 · Study tier 4 · Not human evidence · Benefit · Unreviewed automatic assessment
• Postmarketing Safety Signals and Medication-Use Risks of GLP-1-Based Therapies in Diabetes and Obesity: A Multi-Source Pharmacovigilance and Regulatory Evidence-Mapping StudyPharmacovigilance · 2026 · Study tier 4 · Different population · Harm direction · Unreviewed automatic assessment
• Glucagon-like Peptide-1 Receptor Agonist-Associated Injection Site and Dermatologic ReactionsPharmacovigilance · 2026 · Study tier 4 · Different population · Harm direction · Unreviewed automatic assessment
• The GLP-1 Nutritional Paradox: A Global Meta-Analysis of Sarcopenic Risks and Micronutrient Gaps in the Post-Obesity EraMeta-analysis · 2026 · Preliminary · Different population · Harm direction · Not peer reviewed · Unreviewed automatic assessment
• Real-World EHR Signals from a Cohort of Blinded Incretin Trial Participants Motivate Novel Indication OpportunitiesRetrospective cohort · 2026 · Preliminary · Different population · Null · Not peer reviewed · Unreviewed automatic assessment
• Integrating the liver into the cardiovascular-kidney-metabolic syndrome: pathophysiology and therapeutic implicationsRetrospective cohort · 2026 · Study tier 3 · Different population · Unclear · Unreviewed automatic assessment
• Cardiometabolic outcomes of once-weekly IcoSema in adults with type 2 diabetes: systematic review and meta-analysis of the COMBINE trialsMeta-analysis · 2026 · Study tier 2 · Different population · Benefit · Unreviewed automatic assessment
• Multi-Database Pharmacovigilance Analysis of Gastroesophageal Reflux Disease Associated with GLP-1 Receptor Agonists: A Cross-National Signal Validation StudyPharmacovigilance · 2026 · Study tier 4 · Different population · Harm direction · Unreviewed automatic assessment
• Combination GLP-1RA and Low-Dose IL-2 Modulates Peripheral Immune Activation and Attenuates CNS Inflammatory Transcript Signatures In VivoAnimal study · 2026 · Study tier 4 · Not human evidence · Unclear · Unreviewed automatic assessment
• Higher semaglutide dose is associated with lower neuropsychiatric event incidence independent of weight lossRetrospective cohort · 2026 · Study tier 3 · Different population · Benefit · Unreviewed automatic assessment
• Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists and Co-agonists for Weight Loss Among Adults Without Diabetes : An Updated Systematic ReviewSystematic review · 2026 · Study tier 2 · Different population · Unclear · Unreviewed automatic assessment
• Comparative effectiveness of GLP-1 receptor agonists versus mineralocorticoid receptor antagonists as fourth-line pharmacological therapy in patients with resistant hypertension and overweight or obesity: a retrospective multicenter cohort study in the USARetrospective cohort · 2026 · Study tier 3 · Different population · Unclear · Unreviewed automatic assessment
• Late-life semaglutide treatment slows ageing and extends lifespan in female miceAnimal study · 2026 · Study tier 4 · Not human evidence · Mixed · Unreviewed automatic assessment
• Weight Regain Trajectories After Discontinuation of Semaglutide or Tirzepatide: A Reconstructed Aggregate-Data Bayesian Longitudinal Meta-AnalysisMeta-analysis · 2026 · Study tier 3 · Population unclear · Unclear · Unreviewed automatic assessment
• Assessing Type 2 Diabetes and GLP-1 agonist response trajectories with a proteogenomic atlas of disease progressionMendelian randomization · 2026 · Preliminary · Population unclear · Unclear · Not peer reviewed · Unreviewed automatic assessment
• Intrathecal semaglutide attenuates burn injury-induced pain in mice through a spinal GLP-1R-linked enkephalin/δ-opioid receptor pathwayAnimal study · 2026 · Study tier 4 · Not human evidence · Harm direction · Unreviewed automatic assessment
• Effects of subcutaneous semaglutide on weight loss and inflammatory markers in adults with overweight or obesity without diabetes: a systematic review and meta-analysisMeta-analysis · 2026 · Study tier 2 · Different population · Unclear · Unreviewed automatic assessment
• Effect of Semaglutide on the Inflammatory Biomarker High-Sensitivity CRP in Patients With Established Cardiovascular Disease and Overweight or Obesity in SELECT: A Prespecified Secondary AnalysisPrespecified secondary (sub-study) analysis of a randomized, double-blind, placebo-controlled, parallel-group phase 3 trial (select) · 2026 · Study tier 2 · Different population · Benefit · Industry funded
• The GLP-1-Mitochondria Axis in Metabolic AgingMechanistic review · 2026 · Not rated · Not human evidence · Unclear
• Comparative Efficacy and Safety of Tirzepatide Versus Semaglutide for Obesity: A Systematic ReviewSystematic review · 2026 · Study tier 2 · Different population · Mixed · Unreviewed automatic assessment
• Diabetes, Adiposity, and Functional Phenotypes in HFpEF: A Systematic Review of Recent Treatment-Response EvidenceSystematic review · 2026 · Study tier 2 · Different population · Benefit · Unreviewed automatic assessment
• Neuropsychiatric Effects of Glucagon-Like Peptide-1 Receptor Agonists in Schizophrenia-Spectrum Disorders: A Systematic ReviewSystematic review · 2026 · Study tier 2 · Population unclear · Mixed · Unreviewed automatic assessment
• Incretin-Based Therapies Versus Bariatric and Metabolic Surgery for Obesity and Type 2 Diabetes Mellitus: A Head-to-Head Systematic Review of Glycaemic, Cardiovascular, Hepatic, Weight, and Quality-of-Life OutcomesSystematic review · 2026 · Study tier 2 · Different population · Mixed · Unreviewed automatic assessment
• Investigating the Association Between Semaglutide Use and Mood Disorders in Polyendocrine Metabolic Ovarian Syndrome: A Retrospective Cohort Study​Retrospective cohort · 2026 · Study tier 3 · Population unclear · Unclear · Unreviewed automatic assessment
• FDA prescribing information: Ozempic (SEMAGLUTIDE) - label effective 2026-07-30Regulatory document · 2026 · Not rated · Population unclear · Null · Not peer reviewed · Unreviewed automatic assessment
• Effects of Semaglutide on Body Composition and GFR: A Prespecified Analysis of the SMART TrialRandomized trial · 2026 · Study tier 3 · Different population · Mixed · Industry funded
• Short-term comparative effects of semaglutide, either alone or in conjunction with canagliflozin, on early diabetic kidney diseaseRandomized trial · 2026 · Study tier 3 · Population unclear · Benefit · Unreviewed automatic assessment
• Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trialsRandomized trial · 2026 · Study tier 1 · Partial match · Null · Industry funded
• Effects of Semaglutide on Cognitive Function in People With HIV: A Randomized, Controlled TrialRandomized trial · 2026 · Study tier 3 · Population unclear · Unclear · Unreviewed automatic assessment
• Oral Semaglutide and Change in Cardiovascular Risk Factors in High-Risk Type 2 Diabetes: A Post Hoc Secondary Analysis of the SOUL Randomized Clinical TrialRandomized trial · 2026 · Study tier 1 · Different population · Benefit · Unreviewed automatic assessment
• Semaglutide-associated risk of nonarteritic anterior ischemic optic neuropathy in patients with type 2 diabetes: A systematic review and meta-analysis of observational studiesMeta-analysis · 2026 · Study tier 3 · Different population · Harm direction
• Incretin-Based Therapies in Obesity-Related Heart Failure With Preserved Ejection Fraction (HFpEF): A Systematic Review of Emerging Cardiometabolic Disease Modification Beyond Glycemic ControlSystematic review · 2026 · Study tier 2 · Different population · Mixed · Unreviewed automatic assessment
• FDA prescribing information: OZEMPIC, RYBELSUS (ORAL SEMAGLUTIDE) - label effective 2026-01-30Regulatory document · 2026 · Not rated · Population unclear · Harm direction · Not peer reviewed · Unreviewed automatic assessment
• Weight regain following discontinuation of glucagon-like peptide-1 receptor agonists in adults who are overweight or obese: a systematic review and meta-analysisMeta-analysis · 2026 · Study tier 2 · Different population · Harm direction · Unreviewed automatic assessment
• Reporting patterns of suicide- and self-injury-related events involving liraglutide, semaglutide, and tirzepatide: data from the European pharmacovigilance databasePharmacovigilance · 2026 · Study tier 4 · Different population · Harm direction · Unreviewed automatic assessment
• Use of incretin receptor agonists in patients submitted to metabolic bariatric surgery - a systematic review and meta-analysisMeta-analysis · 2026 · Study tier 3 · Population unclear · Harm direction · Unreviewed automatic assessment
• Comparative efficacy and safety of glucagon-like peptide 1 based drugs for weight loss in adults with overweight or obesity without diabetes: network meta-analysis of randomised controlled trialsMeta-analysis · 2026 · Study tier 2 · Different population · Unclear · Unreviewed automatic assessment
• Association of Tirzepatide versus Semaglutide with Risk of Asthma Exacerbation in Patients with Asthma and Type 2 Diabetes: A US Multicenter Retrospective Cohort StudyRetrospective cohort · 2026 · Study tier 3 · Population unclear · Null · Unreviewed automatic assessment
• Efficacy and Safety of CagriSema for Metabolic Outcomes: Systematic Review and Pairwise Meta-Analysis of Randomized Controlled TrialsMeta-analysis · 2026 · Study tier 2 · Different population · Unclear · Unreviewed automatic assessment
• Divergent effects of semaglutide and CRV431 Co-therapy on liver fibrosis and HCC in MASLD mouse modelAnimal study · 2026 · Study tier 4 · Not human evidence · Mixed · Unreviewed automatic assessment
• Risk of neoplasms with semaglutide in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trialsMeta-analysis · 2026 · Study tier 2 · Different population · Harm direction · Unreviewed automatic assessment
• Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trialRandomized trial · 2025 · Study tier 2 · Different population · Benefit · Industry funded
• Effects of semaglutide in obesity-related heart failure with preserved ejection fraction across the age spectrum: Findings from the STEP-HFpEF programmeRandomized trial · 2025 · Study tier 2 · Different population · Benefit · Unreviewed automatic assessment
• Semaglutide and Exercise Function in Obesity-Related HFpEF: Insights From the STEP-HFpEF ProgramRandomized trial · 2025 · Study tier 1 · Different population · Benefit · Unreviewed automatic assessment
• Effects of combined metformin and semaglutide therapy on body weight, metabolic parameters, and reproductive outcomes in overweight/obese women with polycystic ovary syndrome: a prospective, randomized, controlled, open-label clinical trialRandomized trial · 2025 · Study tier 3 · Different population · Benefit · Unreviewed automatic assessment
• Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated SteatohepatitisRandomized trial · 2025 · Study tier 1 · Different population · Benefit · Industry funded
• Effect of Semaglutide Versus Placebo on Heart Failure With Preserved Ejection Fraction in Obese Patients: A Systematic ReviewSystematic review · 2025 · Study tier 2 · Different population · Benefit · Unreviewed automatic assessment
• Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 DiabetesRandomized trial · 2025 · Study tier 1 · Different population · Benefit · Industry funded
• Efficacy of Semaglutide and Other GLP-1 Agonists in Patients with Heart Failure With Preserved Ejection Fraction and Obesity: A Systemic Review and Meta-AnalysisMeta-analysis · 2025 · Study tier 3 · Different population · Mixed · Unreviewed automatic assessment
• Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical TrialRandomized trial · 2025 · Study tier 3 · Partial match · Benefit
• Efficacy of GLP-1 Receptor Agonist-Based Therapies on Cardiovascular Events and Cardiometabolic Parameters in Obese Individuals Without Diabetes: A Meta-Analysis of Randomized Controlled TrialsMeta-analysis · 2025 · Study tier 2 · Different population · Unclear · Unreviewed automatic assessment
• The Effects of Semaglutide on Inflammation and Immune Activation in HIV-associated LipohypertrophyRandomized trial · 2025 · Study tier 3 · Population unclear · Unclear · Unreviewed automatic assessment
• Effects of Semaglutide Treatment on Psoriatic Lesions in Obese Patients with Type 2 Diabetes Mellitus: An Open-Label, Randomized Clinical TrialRandomized trial · 2025 · Study tier 3 · Different population · Benefit · Unreviewed automatic assessment
• Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trialsMeta-analysis · 2025 · Study tier 1 · Different population · Benefit
• Efficacy and safety of GLP-1 receptor agonists in the treatment of obese patients with chronic heart failure: a meta-analysisMeta-analysis · 2025 · Study tier 3 · Different population · Unclear · Unreviewed automatic assessment
• Associations of semaglutide with first-time diagnosis of Alzheimer's disease in patients with type 2 diabetes: Target trial emulation using nationwide real-world data in the USRetrospective cohort · 2024 · Study tier 4 · Different population · Benefit
• Once-Weekly Semaglutide in Persons with Obesity and Knee OsteoarthritisRandomized trial · 2024 · Study tier 2 · Different population · Benefit · Industry funded
• Atrial Fibrillation and Semaglutide Effects in Obesity-Related Heart Failure With Preserved Ejection Fraction: STEP-HFpEF ProgramRandomized trial · 2024 · Study tier 1 · Different population · Benefit · Unreviewed automatic assessment
• Inflammation in Obesity-Related HFpEF: The STEP-HFpEF ProgramRandomized trial · 2024 · Study tier 1 · Different population · Benefit · Unreviewed automatic assessment
• Efficacy of Semaglutide by Sex in Obesity-Related Heart Failure With Preserved Ejection Fraction: STEP-HFpEF TrialsRandomized trial · 2024 · Study tier 1 · Different population · Benefit · Unreviewed automatic assessment
• Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trialRandomized trial · 2024 · Study tier 2 · Different population · Benefit · Industry funded
• Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed SemaglutideRetrospective cohort · 2024 · Study tier 4 · Different population · Harm direction
• Semaglutide and NYHA Functional Class in Obesity-Related Heart Failure With Preserved Ejection Fraction: The STEP-HFpEF ProgramRandomized trial · 2024 · Study tier 1 · Different population · Benefit · Unreviewed automatic assessment
• Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 DiabetesRandomized trial · 2024 · Study tier 1 · Different population · Benefit · Industry funded
• Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trialRandomized trial · 2024 · Study tier 2 · Different population · Benefit · Industry funded
• Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trialsRandomized trial · 2024 · Study tier 3 · Different population · Benefit · Partly industry funded · Unreviewed automatic assessment
• FDA prescribing information: WEGOVY (SEMAGLUTIDE) - label effective 2024-04-23Regulatory document · 2024 · Not rated · Population unclear · Null · Not peer reviewed · Unreviewed automatic assessment
• Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 DiabetesRandomized trial · 2024 · Study tier 2 · Different population · Unclear · Industry funded · Unreviewed automatic assessment
• Efficacy and safety of semaglutide 2.4 mg for weight loss in overweight or obese adults without diabetes: An updated systematic review and meta-analysis including the 2-year STEP 5 trialMeta-analysis · 2024 · Study tier 2 · Different population · Unclear · Unreviewed automatic assessment
• Effects of Semaglutide on Symptoms, Function, and Quality of Life in Patients With Heart Failure With Preserved Ejection Fraction and Obesity: A Prespecified Analysis of the STEP-HFpEF TrialRandomized trial · 2024 · Study tier 2 · Different population · Benefit · Unreviewed automatic assessment
• Association of semaglutide with risk of suicidal ideation in a real-world cohortRetrospective cohort · 2024 · Study tier 3 · Different population · Null
• Oral Adverse Effects of Semaglutide Therapy: A Narrative ReviewPharmacovigilance · 2024 · Study tier 4 · Different population · Harm direction · Unreviewed automatic assessment
• Anti-inflammatory effect of semaglutide: updated systematic review and meta-analysisMeta-analysis · 2024 · Study tier 2 · Different population · Unclear · Unreviewed automatic assessment
• Semaglutide and Cardiovascular Outcomes in Obesity without DiabetesRandomized trial · 2023 · Study tier 1 · Different population · Benefit · Industry funded
• Semaglutide in Patients With Obesity and Heart Failure Across Mildly Reduced or Preserved Ejection FractionDesign unknown · 2023 · Not rated · Population unclear · Benefit · Unreviewed automatic assessment
• FDA prescribing information: Ozempic (SEMAGLUTIDE) - label effective 2023-11-22Regulatory document · 2023 · Not rated · Population unclear · Null · Not peer reviewed · Unreviewed automatic assessment
• FDA prescribing information: OZEMPIC (SEMAGLUTIDE) - label effective 2023-11-17Regulatory document · 2023 · Not rated · Population unclear · Null · Not peer reviewed · Unreviewed automatic assessment
• Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight LossRetrospective cohort · 2023 · Study tier 3 · Different population · Harm direction
• Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and ObesityRandomized, double-blind, placebo-controlled, parallel-group, multicentre, phase 3 trial; 52-week treatment period · 2023 · Study tier 2 · Different population · Benefit
• Effects of once-weekly semaglutide 2.4 mg on C-reactive protein in adults with overweight or obesity (STEP 1, 2, and 3): Exploratory analyses of three randomised, double-blind, placebo-controlled, phase 3 trialsRandomized trial · 2023 · Study tier 3 · Different population · Unclear · Industry funded · Unreviewed automatic assessment
• Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trialsRandomized trial · 2022 · Study tier 1 · Different population · Unclear · Unreviewed automatic assessment
• Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extensionRandomized trial · 2022 · Study tier 2 · Different population · Harm direction · Industry funded
• Efficacy and safety of semaglutide on weight loss in obese or overweight patients without diabetes: A systematic review and meta-analysis of randomized controlled trialsMeta-analysis · 2022 · Study tier 2 · Different population · Harm direction · Unreviewed automatic assessment
• Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trialsMeta-analysis · 2021 · Study tier 1 · Different population · Benefit
• Once-Weekly Semaglutide in Adults with Overweight or ObesityRandomized trial · 2021 · Study tier 1 · Different population · Benefit · Industry funded
• Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesityDesign unknown · 2019 · Not rated · Population unclear · Unclear · Partly industry funded · Unreviewed automatic assessment
• Semaglutide and Cardiovascular Outcomes in Patients with Type 2 DiabetesRandomized trial · 2016 · Study tier 2 · Different population · Mixed · Industry funded
• Benefits and Harms of Once-Weekly Glucagon-like Peptide-1 Receptor Agonist Treatments: A Systematic Review and Network Meta-analysisMeta-analysis · 2016 · Study tier 2 · Different population · Unclear · Unreviewed automatic assessment